Literature DB >> 23410039

Regulation of cholinergic activity by the vesicular acetylcholine transporter.

Vania F Prado1, Ashbeel Roy, Benjamin Kolisnyk, Robert Gros, Marco A M Prado.   

Abstract

Acetylcholine, the first chemical to be identified as a neurotransmitter, is packed in synaptic vesicles by the activity of VAChT (vesicular acetylcholine transporter). A decrease in VAChT expression has been reported in a number of diseases, and this has consequences for the amount of acetylcholine loaded in synaptic vesicles as well as for neurotransmitter release. Several genetically modified mice targeting the VAChT gene have been generated, providing novel models to understand how changes in VAChT affect transmitter release. A surprising finding is that most cholinergic neurons in the brain also can express a second type of vesicular neurotransmitter transporter that allows these neurons to secrete two distinct neurotransmitters. Thus a given neuron can use two neurotransmitters to regulate different physiological functions. In addition, recent data indicate that non-neuronal cells can also express the machinery used to synthesize and release acetylcholine. Some of these cells rely on VAChT to secrete acetylcholine with potential physiological consequences in the periphery. Hence novel functions for the oldest neurotransmitter known are emerging with the potential to provide new targets for the treatment of several pathological conditions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23410039     DOI: 10.1042/BJ20121662

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  37 in total

1.  Kinetics modeling and occupancy studies of a novel C-11 PET tracer for VAChT in nonhuman primates.

Authors:  Hongjun Jin; Xiang Zhang; Xuyi Yue; Hui Liu; Junfeng Li; Hao Yang; Hubert Flores; Yi Su; Stanley M Parsons; Joel S Perlmutter; Zhude Tu
Journal:  Nucl Med Biol       Date:  2015-11-07       Impact factor: 2.408

2.  Phosphorylation at serine 31 targets tyrosine hydroxylase to vesicles for transport along microtubules.

Authors:  Ana Jorge-Finnigan; Rune Kleppe; Kunwar Jung-Kc; Ming Ying; Michael Marie; Ivan Rios-Mondragon; Michael F Salvatore; Jaakko Saraste; Aurora Martinez
Journal:  J Biol Chem       Date:  2017-06-21       Impact factor: 5.157

3.  Forebrain deletion of the vesicular acetylcholine transporter results in deficits in executive function, metabolic, and RNA splicing abnormalities in the prefrontal cortex.

Authors:  Benjamin Kolisnyk; Mohammed A Al-Onaizi; Pedro H F Hirata; Monica S Guzman; Simona Nikolova; Shahar Barbash; Hermona Soreq; Robert Bartha; Marco A M Prado; Vania F Prado
Journal:  J Neurosci       Date:  2013-09-11       Impact factor: 6.167

4.  Kinetic modeling of [18 F]VAT, a novel radioligand for positron emission tomography imaging vesicular acetylcholine transporter in non-human primate brain.

Authors:  Hongjun Jin; Xuyi Yue; Hui Liu; Junbin Han; Hubert Flores; Yi Su; Stanley M Parsons; Joel S Perlmutter; Zhude Tu
Journal:  J Neurochem       Date:  2018-03-25       Impact factor: 5.372

5.  Immunolocalization of the vesicular acetylcholine transporter in larval and adult Drosophila neurons.

Authors:  Sridhar Boppana; Natalie Kendall; Opeyemi Akinrinsola; Daniel White; Krushali Patel; Hakeem Lawal
Journal:  Neurosci Lett       Date:  2017-02-07       Impact factor: 3.046

Review 6.  Nicotinic ACh receptors as therapeutic targets in CNS disorders.

Authors:  Kelly T Dineley; Anshul A Pandya; Jerrel L Yakel
Journal:  Trends Pharmacol Sci       Date:  2015-01-29       Impact factor: 14.819

7.  Cardiomyocyte-secreted acetylcholine is required for maintenance of homeostasis in the heart.

Authors:  Ashbeel Roy; William C Fields; Cibele Rocha-Resende; Rodrigo R Resende; Silvia Guatimosim; Vania F Prado; Robert Gros; Marco A M Prado
Journal:  FASEB J       Date:  2013-09-09       Impact factor: 5.191

8.  The Concise Guide to PHARMACOLOGY 2013/14: transporters.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

9.  Development of a model system for neuronal dysfunction in Fabry disease.

Authors:  Christine R Kaneski; Roscoe O Brady; John A Hanover; Ulrike H Schueler
Journal:  Mol Genet Metab       Date:  2016-07-22       Impact factor: 4.797

Review 10.  Reassessment of the role of the central cholinergic system.

Authors:  Anna Hrabovska; Eric Krejci
Journal:  J Mol Neurosci       Date:  2013-11-10       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.